𝔖 Bobbio Scriptorium
✦   LIBER   ✦

140Safety, tolerability and drug interactions of adjuvant imatinib mesylate (GLEEVEC®) within the first 100 days following stem cell transplantation (SCT) in patients with PH+ CML and PH+ all at high risk for recurrence

✍ Scribed by S.R. Sheth; K. Hicks; C. Ippoliti; S. Giralt; R.E. Champlin; P. Anderlini


Book ID
117728146
Publisher
Elsevier Science
Year
2003
Tongue
English
Weight
137 KB
Volume
9
Category
Article
ISSN
1083-8791

No coin nor oath required. For personal study only.